Disease or Syndrome – Page 80

Bioptimus Secures $76M Funding to Develop Revolutionary AI Foundation Model for Biology

10 months ago talkbio0Tagged Alanine Transaminase, Artificial Intelligence, biology (field), Bioptimus, Cathay Innovation, Drug Industry, medical innovation, Study models

Bioptimus, AI foundation model, biology, funding, Cathay Innovation, GPT of biology, biological research, pharmaceutical industry, biotech, medical innovation.

Denali and AbbVie’s ALS Candidates Fail Phase 2/3 Trials, Highlighting Challenges in ALS Research

10 months ago talkbio0Tagged AbbVie, Amyotrophic Lateral Sclerosis, Calico Life Sciences, Clinical Trials, Denali, DNL343, Drug Development, fosigotifator, HEALEY

ALS, Denali Therapeutics, AbbVie, Calico Life Sciences, HEALEY ALS Platform Trial, DNL343, fosigotifator, amyotrophic lateral sclerosis, clinical trials, drug development

Hengrui and Kailera’s Obesity Drug HRS9531 Shows Promising Results in Phase 2 Trial

10 months ago talkbio0Tagged GLP-1/GIP receptor dual agonist, Hengrui Pharmaceuticals, Kailera, Obesity, Phase 2 clinical trial, Weight Loss

HRS9531, Obesity treatment, GLP-1/GIP receptor dual agonist, Phase 2 clinical trial, Weight loss, Hengrui Pharmaceuticals, Kailera Therapeutics

Moderna Slashes 2025 Revenue Forecast, Expands Cost-Cutting Measures Amid Vaccine Sales Decline

10 months ago talkbio0Tagged 2025, competition, cost-cutting measures, COVID19 (disease), decline, Market, Moderna, Vaccination, Vaccines

Moderna, 2025 revenue forecast, cost-cutting measures, vaccine sales decline, COVID-19 vaccine market competition, falling vaccination rates.

Gilead Sciences Expands into Inflammatory Diseases with $1.7 Billion Collaboration with LEO Pharma

10 months ago talkbio0Tagged Asthma, COPD, Eczema, Gilead Sciences, Inflammatory disorder, inhibitors, JPM25, Pharma, STAT6

Gilead Sciences, LEO Pharma, STAT6 inhibitors, inflammatory diseases, eczema, asthma, COPD, biotech deal, JPM25

Regor’s Obesity Pill RGT-075 Shows Moderate Weight Loss in Phase 2a, Advances to Phase 2b Trial

10 months ago talkbio0Tagged GLP-1 receptor, Obesity, Oral Medication, phase 2a, Phase 2b Trial, RGT-075

RGT-075, obesity treatment, GLP-1 receptor agonist, oral medication, Phase 2a results, Phase 2b trial

Gilead and LEO Pharma Collaborate on STAT6 Inflammatory Disease Programmes

10 months ago talkbio0Tagged Dermatology field, Gilead Sciences, Inflammatory disorder, oral formulations, Partnership, Pharma, STAT6

Gilead Sciences, LEO Pharma, STAT6, inflammatory diseases, partnership, oral formulations, dermatology

Eli Lilly and Mediar Therapeutics Collaborate on Novel IPF Treatment with $780M+ Deal

10 months ago talkbio0Tagged Antibodies, CCN4 gene, Clinical Trials, Eli, Eli Lilly, Fibrosis, Idiopathic Pulmonary Fibrosis, licensing agreement, MTX-463

Eli Lilly, Mediar Therapeutics, Idiopathic Pulmonary Fibrosis (IPF), MTX-463, WISP1 antibody, fibrosis treatment, licensing agreement, clinical trials.

Bausch + Lomb Collaborates with City Therapeutics on Novel RNAi-Based Treatment for Geographic Atrophy

10 months ago talkbio0Tagged Age related macular degeneration, Bausch, Cities, Geographic Atrophy, Lomb, Ophthalmologic diseases, RNA Interference, strategic collaboration

Bausch + Lomb, City Therapeutics, RNA interference (RNAi), Geographic atrophy (GA), Age-related macular degeneration (AMD), Strategic collaboration, Ophthalmologic diseases

2024 FDA Approvals: Breakthroughs in Cancer and Rare Diseases

10 months ago talkbio0Tagged 2024, approvals, cancer treatments, United States Food and Drug Administration

FDA approvals, 2024, cancer treatments, rare diseases, novel drugs